Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Adults With Generalized Myasthenia Gravis
NCT04951622Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of nipocalimab in myasthenia gravis (MG) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Myasthenia Gravis - Activities of Daily Living Total Score at 24 weeks, Anti-AChR Autoantibody Titer at 8 weeks and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04951622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951622.